Compositions, methods and kits relating to remodel
AssigneeMaine Medical Center Research Institute
InventorsVolkhard Lindner, Robert E. Friesel
Life of this patent
Estimating the term…
Abstract
The invention relates to novel nucleic acids encoding a mammalian adventitia inducible and bone expressed gene designated REMODEL, and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, negative remodeling, arterial restenosis, vessel injury, ectopic ossification, fibrosis, and the like. REMODEL also plays a role in cell-cell and cell-matrix adhesion, bone density, bone formation, dorsal closure, and is associated with spina bifida-like phenotype. The invention further relates to methods of treating and detecting these diseases, disorders or conditions, comprising modulating or detecting REMODEL expression and/or production of REMODEL polypeptide.
Claims36
An isolated nucleic acid encoding a mammalian REMODEL, or a fragment thereof.
An isolated nucleic acid encoding a mammalian REMODEL, wherein the amino acid sequence of said REMODEL shares at least about 6% sequence identity with an amino acid sequence of at least one of SEQ ID NO:2, SEQ ID NO:4, and SEQ ID NO:5.
An isolated polypeptide comprising a mammalian REMODEL.
An antibody that specifically binds with a mammalian REMODEL molecule polypeptide, or a fragment thereof.
A method of diagnosing arterial restenosis in a previously undiagnosed mammal, said method comprising obtaining a biological sample from said mammal, assessing the level of REMODEL in said biological sample, and comparing the level of REMODEL in said biological sample with the level of REMODEL in a biological sample obtained from a like mammal not afflicted with arterial restenosis, wherein a higher level of REMODEL in said biological sample from said mammal compared with the level of REMODEL in said biological sample from said like mammal is an indication that said mammal is afflicted with arterial restenosis, thereby diagnosing arterial restenosis in said previously undiagnosed mammal.
A method of diagnosing negative remodeling in a previously undiagnosed mammal, said method comprising obtaining a biological sample from said mammal, assessing the level of REMODEL in said biological sample, and comparing the level of REMODEL in said biological sample with the level of REMODEL in a biological sample obtained from a like mammal not afflicted with negative remodeling, wherein a higher level of REMODEL in said biological sample from said mammal compared with the level of REMODEL in said biological sample from said like mammal is an indication that said mammal is afflicted with negative remodeling, thereby diagnosing negative remodeling in said previously undiagnosed mammal.
A method of diagnosing fibrosis in a previously undiagnosed mammal, said method comprising obtaining a biological sample from said mammal, assessing the level of REMODEL in said biological sample, and comparing the level of REMODEL in said biological sample with the level of REMODEL in a biological sample obtained from a like mammal not afflicted with fibrosis, wherein a higher level of REMODEL in said biological sample from said mammal compared with the level of REMODEL in said biological sample from said like mammal is an indication that said mammal is afflicted with fibrosis, thereby diagnosing fibrosis in said previously undiagnosed mammal.
A method of identifying a compound that affects expression of REMODEL in a cell, said method comprising contacting a cell with a test compound and comparing the level of REMODEL expression in said cell with the level of REMODEL expression in an otherwise identical cell not contacted with said test compound, wherein a higher or lower level of REMODEL expression in said cell contacted with said test compound compared with the level of REMODEL expression in said otherwise identical cell not contacted with said test compound is an indication that said test compound affects expression of REMODEL in a cell.
A method of identifying a compound that reduces expression of REMODEL in a cell, said method comprising contacting a cell with a test compound and comparing the level of REMODEL expression in said cell with the level of REMODEL expression in an otherwise identical cell not contacted with said test compound, wherein a lower level of REMODEL expression in said cell contacted with said test compound compared with the level of REMODEL expression in said otherwise identical cell not contacted with said test compound is an indication that said test compound reduces expression of REMODEL in a cell.
A method of identifying a compound that affects TGF-β signaling, said method comprising contacting a cell with a test compound and comparing the level of REMODEL expression in said cell with the level of REMODEL expression in an otherwise identical cell not contacted with said test compound, wherein a higher or lower level of REMODEL expression in said cell contacted with said test compound compared with the level of REMODEL expression in said otherwise identical cell not contacted with said test compound is an indication that said test compound affects TGF-β signaling in a cell.
Dependencies are inferred from the claim text.